Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5.

Gazzah A, Ricordel C, Italiano A, Cho BC, Calvo E, Kim DW, Helissey C, Kim JS, Villar MV, Ghiringhelli F, Moreno V, Cousin S, Paz-Ares L, Fagniez N, Chadjaa M, Bauchet AL, Soufflet C, Masson N, Barlesi F

Open source

DOI: 10.1016/j.jtocrr.2025.100844
Published: 2025 Oct
Container: JTO clinical and research reports
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtocrr.2025.100844,
  title = {Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5.},
  author = {Gazzah A and Ricordel C and Italiano A and Cho BC and Calvo E and Kim DW and Helissey C and Kim JS and Villar MV and Ghiringhelli F and Moreno V and Cousin S and Paz-Ares L and Fagniez N and Chadjaa M and Bauchet AL and Soufflet C and Masson N and Barlesi F},
  year = {2025},
  journal = {JTO clinical and research reports},
  doi = {10.1016/j.jtocrr.2025.100844},
  url = {https://doi.org/10.1016/j.jtocrr.2025.100844}
}

RIS

TY  - JOUR
TI  - Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5.
AU  - Gazzah A
AU  - Ricordel C
AU  - Italiano A
AU  - Cho BC
AU  - Calvo E
AU  - Kim DW
AU  - Helissey C
AU  - Kim JS
AU  - Villar MV
AU  - Ghiringhelli F
AU  - Moreno V
AU  - Cousin S
AU  - Paz-Ares L
AU  - Fagniez N
AU  - Chadjaa M
AU  - Bauchet AL
AU  - Soufflet C
AU  - Masson N
AU  - Barlesi F
PY  - 2025
JO  - JTO clinical and research reports
DO  - 10.1016/j.jtocrr.2025.100844
UR  - https://doi.org/10.1016/j.jtocrr.2025.100844
ER  -

APA

A, G., C, R., A, I., BC, C., E, C., DW, K., C, H., JS, K., MV, V., F, G., V, M., S, C., L, P., N, F., M, C., AL, B., C, S., N, M., & F, B. (2025). Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2025.100844

Source records

pubmed · retrieved 2026-09-26T04:18:02.749Z